Log in

RedHill Biopharma Stock Forecast, Price & News

+0.23 (+2.70 %)
(As of 10/29/2020 12:00 AM ET)
Today's Range
Now: $8.74
50-Day Range
MA: $10.02
52-Week Range
Now: $8.74
Volume153,463 shs
Average Volume363,704 shs
Market Capitalization$326.95 million
P/E RatioN/A
Dividend YieldN/A
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal diseases. The company promotes various gastrointestinal drugs, including Movantik for opioid-induced constipation in adults; Talicia for the treatment of Helicobacter pylori bacterial infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its late-stage clinical development programs include RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), a sphingosine kinase-2 selective inhibitors targeting multiple indications with a Phase 2/3 program for COVID-19 and ongoing Phase 2 studies for prostate cancer and cholangiocarcinoma; RHB-104, which is in Phase 3 study for treating Crohn's disease; RHB-102 (Bekinda) with positive results from a Phase 3 study for acute gastroenteritis and gastritis, and positive results from a Phase 2 study for irritable bowel syndrome with diarrhea; RHB-106, an encapsulated bowel preparation; and RHB-107, a Phase 2-stage serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases and is also being evaluated for COVID-19. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
Read More
RedHill Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RDHL



Sales & Book Value

Annual Sales$6.29 million
Book Value$2.74 per share


Net Income$-42,300,000.00
Net Margins-219.39%


Market Cap$326.95 million
Next Earnings Date11/17/2020 (Estimated)
+0.23 (+2.70 %)
(As of 10/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RDHL News and Ratings via Email

Sign-up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

RedHill Biopharma (NASDAQ:RDHL) Frequently Asked Questions

How has RedHill Biopharma's stock price been impacted by Coronavirus?

RedHill Biopharma's stock was trading at $3.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RDHL shares have increased by 119.0% and is now trading at $8.74.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of RedHill Biopharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RedHill Biopharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for RedHill Biopharma

When is RedHill Biopharma's next earnings date?

RedHill Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, November 17th 2020.
View our earnings forecast for RedHill Biopharma

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd. (NASDAQ:RDHL) issued its quarterly earnings data on Thursday, August, 13th. The biotechnology company reported ($0.45) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.31. The biotechnology company earned $20.90 million during the quarter, compared to analysts' expectations of $20.52 million. RedHill Biopharma had a negative net margin of 219.39% and a negative return on equity of 135.90%.
View RedHill Biopharma's earnings history

What price target have analysts set for RDHL?

3 brokers have issued 1 year price objectives for RedHill Biopharma's stock. Their forecasts range from $14.00 to $26.00. On average, they expect RedHill Biopharma's stock price to reach $19.25 in the next twelve months. This suggests a possible upside of 120.3% from the stock's current price.
View analysts' price targets for RedHill Biopharma

Are investors shorting RedHill Biopharma?

RedHill Biopharma saw a drop in short interest in the month of September. As of September 30th, there was short interest totaling 1,590,000 shares, a drop of 20.5% from the September 15th total of 2,000,000 shares. Based on an average daily volume of 393,400 shares, the days-to-cover ratio is currently 4.0 days.
View RedHill Biopharma's Short Interest

Who are some of RedHill Biopharma's key competitors?

What other stocks do shareholders of RedHill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA).

Who are RedHill Biopharma's key executives?

RedHill Biopharma's management team includes the following people:
  • Mr. Dror Ben-Asher, Co-Founder, Chairman & CEO (Age 54, Pay $448.42k)
  • Mr. Micha Ben-Chorin, Chief Financial Officer (Age 51, Pay $339.01k)
  • Mr. Gilead Raday, Chief Operating Officer (Age 45, Pay $361.68k)
  • Mr. Adi Frish, Sr. VP of Bus. Devel. & Licensing (Age 50, Pay $338.12k)
  • Mr. Guy Goldberg, Chief Bus. Officer (Age 44, Pay $338.13k)

What is RedHill Biopharma's stock symbol?

RedHill Biopharma trades on the NASDAQ under the ticker symbol "RDHL."

Who are RedHill Biopharma's major shareholders?

RedHill Biopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (0.05%) and CIBC Private Wealth Group LLC (0.03%).

Which major investors are selling RedHill Biopharma stock?

RDHL stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC.

Which major investors are buying RedHill Biopharma stock?

RDHL stock was purchased by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC.

How do I buy shares of RedHill Biopharma?

Shares of RDHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is RedHill Biopharma's stock price today?

One share of RDHL stock can currently be purchased for approximately $8.74.

How big of a company is RedHill Biopharma?

RedHill Biopharma has a market capitalization of $326.95 million and generates $6.29 million in revenue each year. The biotechnology company earns $-42,300,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. RedHill Biopharma employs 155 workers across the globe.

What is RedHill Biopharma's official website?

The official website for RedHill Biopharma is www.redhillbio.com.

How can I contact RedHill Biopharma?

RedHill Biopharma's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The biotechnology company can be reached via phone at 972-3541-3131 or via email at [email protected]

This page was last updated on 10/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.